Monica Trevino1, Susan Padalecki2, Anand Karnad3, Alberto Parra4, Steve Weitman5, Melissa Nashawati1, Brad H Pollock6, Amelie Ramirez7, Ian M Thompson2. 1. Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA. 2. Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA ; Departments of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA. 3. Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA ; Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA. 4. Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA. 5. Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA ; Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, USA. 6. Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA ; Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, USA. 7. Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA ; Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, USA ; Institute for Health Promotions Research, University of Texas Health Science Center at San Antonio, San Antonio, USA.
Abstract
BACKGROUND: Cancer does not occur in all ethnic and racial groups at similar rates. In addition, responses to treatment also vary in certain ethnic and racial groups. For Hispanics, the overall cancer incidence is generally lower yet for some specific tumor types, the incidence rates are higher compared to other populations. OBJECTIVES: Although disparities are recognized for treatment outcomes and prevention methodologies for Hispanics and other minority populations, specific recruiting and reporting of minorities remains a challenge. In order to circumvent this problem, the Cancer Therapy and Research Center (CTRC) has developed a new minority recruitment plan for all cancer related clinical trials at this Institute. The overall goal of this initiative is to increase the accrual of minorities in cancer clinical trials by implementing several key interventions. METHOD: The Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio established the Clinical Trials Accrual Task Force to develop and monitor interventions designed to increase accrual to cancer clinical trials, specifically the accrual of minorities with a focus on the Hispanic population that makes up 68% of the CTRC's catchment area. RESULTS: A Minority Accrual Plan (MAP) was implemented in March 2013 as part of the process for initiating and conducting cancer-related clinical trials at the CTRC. The Minority Accrual Plan focuses on Hispanic enrollment due to the characteristics of the South Texas population served by the CTRC but could be easily adapted to other populations. CONCLUSIONS: The CTRC has designed a process to prospectively address the challenge of deliberately enrolling minority subjects and accurately accounting for the results by implementing a Minority Accrual Plan for every cancer-related clinical trial at CTRC.
BACKGROUND:Cancer does not occur in all ethnic and racial groups at similar rates. In addition, responses to treatment also vary in certain ethnic and racial groups. For Hispanics, the overall cancer incidence is generally lower yet for some specific tumor types, the incidence rates are higher compared to other populations. OBJECTIVES: Although disparities are recognized for treatment outcomes and prevention methodologies for Hispanics and other minority populations, specific recruiting and reporting of minorities remains a challenge. In order to circumvent this problem, the Cancer Therapy and Research Center (CTRC) has developed a new minority recruitment plan for all cancer related clinical trials at this Institute. The overall goal of this initiative is to increase the accrual of minorities in cancer clinical trials by implementing several key interventions. METHOD: The Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio established the Clinical Trials Accrual Task Force to develop and monitor interventions designed to increase accrual to cancer clinical trials, specifically the accrual of minorities with a focus on the Hispanic population that makes up 68% of the CTRC's catchment area. RESULTS: A Minority Accrual Plan (MAP) was implemented in March 2013 as part of the process for initiating and conducting cancer-related clinical trials at the CTRC. The Minority Accrual Plan focuses on Hispanic enrollment due to the characteristics of the South Texas population served by the CTRC but could be easily adapted to other populations. CONCLUSIONS: The CTRC has designed a process to prospectively address the challenge of deliberately enrolling minority subjects and accurately accounting for the results by implementing a Minority Accrual Plan for every cancer-related clinical trial at CTRC.
Authors: Robert E Schoen; Paul F Pinsky; Joel L Weissfeld; Lance A Yokochi; Timothy Church; Adeyinka O Laiyemo; Robert Bresalier; Gerald L Andriole; Saundra S Buys; E David Crawford; Mona N Fouad; Claudine Isaacs; Christine C Johnson; Douglas J Reding; Barbara O'Brien; Danielle M Carrick; Patrick Wright; Thomas L Riley; Mark P Purdue; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok; Christine D Berg Journal: N Engl J Med Date: 2012-05-21 Impact factor: 91.245
Authors: Amelie G Ramirez; Eliseo J Pérez-Stable; Frank J Penedo; Gregory A Talavera; J Emilio Carrillo; Maria E Fernandez; Alan E C Holden; Edgar Munoz; Sandra San Miguel; Kip Gallion Journal: Cancer Date: 2012-12-10 Impact factor: 6.860
Authors: B H Pollock; M R DeBaun; B M Camitta; J J Shuster; Y Ravindranath; D J Pullen; V J Land; D H Mahoney; S J Lauer; S B Murphy Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Susan Hariri; Elizabeth R Unger; Suzanne E Powell; Heidi M Bauer; Nancy M Bennett; Karen C Bloch; Linda M Niccolai; Sean Schafer; Martin Steinau; Lauri E Markowitz Journal: J Infect Dis Date: 2012-10-08 Impact factor: 5.226
Authors: Joseph M Herman; Aaron T Wild; Hao Wang; Phuoc T Tran; Kenneth J Chang; Gretchen E Taylor; Ross C Donehower; Timothy M Pawlik; Mark A Ziegler; Hongyan Cai; Dionne T Savage; Marcia I Canto; Jason Klapman; Tony Reid; Raj J Shah; Sarah E Hoffe; Alexander Rosemurgy; Christopher L Wolfgang; Daniel A Laheru Journal: J Clin Oncol Date: 2013-01-22 Impact factor: 44.544
Authors: Ahmedin Jemal; Edgar P Simard; Christina Dorell; Anne-Michelle Noone; Lauri E Markowitz; Betsy Kohler; Christie Eheman; Mona Saraiya; Priti Bandi; Debbie Saslow; Kathleen A Cronin; Meg Watson; Mark Schiffman; S Jane Henley; Maria J Schymura; Robert N Anderson; David Yankey; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2013-01-07 Impact factor: 13.506
Authors: Amelie G Ramirez; Nancy S Weiss; Alan E C Holden; Lucina Suarez; Sharon P Cooper; Edgar Munoz; Susan L Naylor Journal: PLoS One Date: 2012-04-18 Impact factor: 3.240
Authors: Arthur E Frankel; Keith T Flaherty; George J Weiner; Robert Chen; Nilofer S Azad; Michael J Pishvaian; John A Thompson; Matthew H Taylor; Daruka Mahadevan; A Craig Lockhart; Ulka N Vaishampayan; Jordan D Berlin; David C Smith; John Sarantopoulos; Matthew Riese; Mansoor N Saleh; Chul Ahn; Eugene P Frenkel Journal: Oncologist Date: 2017-03-17